Table 1.
Hematologic and renal characteristics of 18 patients with CMML or myeloproliferative neoplasms
| Gender Patient number |
Age, yr | Hematologic |
Delaya | Basal status |
Renal presentation |
Kidney pathology |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Malignancy (mutation) | GFR | CKDb | AKIb | Hu | uPCr | Diagnosis | Mesangial sclerosis | Extramedullary hematopoiesis (CD61 staining) | Immune deposits | |||
| M1 | 75 | MP-CMML-1 Del (7q) |
4 | 73 | 1 | 0 | Yes | 3 | FSGS; AIN | Mild | Glomeruli and interstitium (+) | none |
| F2 | 69 | MD-CMML-2 N/A |
3 | 55 | 2 | 1 | No | 0.6 | CTIN | none | none (–) | none |
| M3 | 79 | MD-CMML-1 N/A |
1 | 18 | 4 | 3 | No | 3.6 | AIN; T-cells infiltrate |
none | none (NA) | none |
| F4 | 79 | MP-CMML-0 KITD816 |
1 | 69 | 1 | 2 | Yes | 0.4 | AIN | Mild | Interstitial (+) | none |
| M5 | 66 | MP-CMML-0 ASXL1 |
0 | 75 | 1 | 3 | Yes | 1.3 | AIN, massive infiltration by CMML | none | Glomeruli and interstitium (NA) | N/A |
| M6 | 63 | MP-CMML-1 N/A |
0 | 56 | 3 | 1 | Yes | 1 | FSGS | none | Glomeruli (+) | N/A |
| F7 | 75 | MP-CMML-1 X chro. |
3 | 87 | 1 | 3 | Yes | 1 | CTIN | none | none | none |
| M8 | 72 | MP-CMML-0 JAK2 |
0 | 55 | 3 | 3 | Yes | 0.9 | Massive EMH | none | Glomeruli and interstitium (+) | none |
| M9 | 40 | ET CALR |
5 | 96 | 1 | 1 | Yes | 3.2 | IgAN; FSGS | Mild | none | IgAλ |
| M10 | 84 | ET JAK2 |
12 | 55 | 3 | 0 | No | 3.2 | AA amyloidosis; CTIN | none | none | N/A |
| M11 | 86 | ET None |
24 | 43 | 3 | 1 | No | 0.2 | N/A | N/A | N/A | N/A |
| M12 | 56 | ET None |
25 | 128 | 1 | 3 | Yes | 2.7 | IgAN | Severe | none | IgA C3 |
| F13 | 80 | ET JAK2 |
14 | 75 | 2 | 0 | No | 13 | FSGS | Mild | Glomeruli and interstitium (+) | none |
| M14 | 74 | ET MPL, DNMT3A |
0 | 64 | 2 | 0 | No | 1 | CTIN | Mild | none (–) | none |
| M15 | 67 | ET JAK2 |
0 | 96 | 1 | 2 | No | <0.2 | N/A | N/A | N/A | N/A |
| M16 | 59 | PV Tri. 8 |
26 | 23 | 4 | 1 | Yes | 7.7 | N/A | N/A | N/A | N/A |
| M17 | 65 | PMF JAK2 |
1 | 48 | 3 | 0 | No | 0.4 | N/A | N/A | N/A | N/A |
| F18 | 71 | SMF (PV) JAK2 | 11 | 38 | 3 | 0 | Yes | 4.4 | FSGS | Mild | none (–) | IgM, C3, C1q (rare) |
AIN, acute interstitial nephropathy; AKI, acute kidney injury; CKD, chronic kidney disease; CMML, chronic myelomonocytic leukemia; CTIN, chronic tubulointerstitial nephropathy; EMH, extramedullary hematopoiesis; ET, essential thrombocytosis; FSGS, focal and segmental glomerulosclerosis; GFR, glomerular filtration rate; Hu, hematuria; IgAN, IgA nephropathy; MD, myelodysplastic; MP, myeloproliferative; PMF, primary myelofibrosis; PV, polycythemia vera; SMF, secondary myelofibrosis; uPCR, urinary protein-to-creatinine ratio (g/g).
Delay from the diagnosis of myeloid neoplasm to the onset of the kidney disease (in years).
CKD and AKI stage according to the KDIGO classifications.